Annual report [Section 13 and 15(d), not S-K Item 405]

Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details)

v3.26.1
Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Income (loss) from discontinued operations $ 8,644 $ (3,839)
Pharmaloz | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenues, net 0 6,442
Cost of revenues 0 7,364
Gross profit (loss) 0 (922)
Operating expenses:    
General and administration 102 2,569
Research and development 0 0
Total operating expenses 102 2,569
Loss from operations (102) (3,491)
Interest expense 0 (378)
Other income 0 30
Income (loss) from discontinued operations $ (102) $ (3,839)